Vivos Therapeutics, Inc. (VVOS)

Market Cap	10.43M -45.2%
Revenue (ttm)	17.32M +18.8%
Net Income	-17.10M
EPS	-1.91
Shares Out	8.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,439
Open	1.150
Previous Close	1.150
Day's Range	1.090 - 1.200
52-Week Range	1.090 - 7.950
Beta	7.01
Analysts	Strong Buy
Price Target	6.25 (+438.79%)
Earnings Date	May 14, 2026

About VVOS

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related t...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 262
• Stock Exchange: NASDAQ
• Ticker Symbol: VVOS
• Website: https://www.vivos.com

Financial Performance

In 2024, Vivos Therapeutics's revenue was $15.03 million, an increase of 8.91% compared to the previous year's $13.80 million. Losses were -$11.14 million, -18.02% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price target is $6.25, which is an increase of 438.79% from the latest price.

Price Target

$6.25

(438.79% upside)

Analyst Consensus: Strong Buy